Voya Investment Management LLC Increases Position in Hims & Hers Health, Inc. $HIMS

Voya Investment Management LLC lifted its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 47.0% in the third quarter, HoldingsChannel.com reports. The fund owned 163,773 shares of the company’s stock after acquiring an additional 52,370 shares during the period. Voya Investment Management LLC’s holdings in Hims & Hers Health were worth $9,289,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of the business. HighTower Advisors LLC bought a new position in Hims & Hers Health in the 1st quarter valued at $482,000. American Century Companies Inc. boosted its holdings in shares of Hims & Hers Health by 31.5% in the 1st quarter. American Century Companies Inc. now owns 185,065 shares of the company’s stock worth $5,469,000 after buying an additional 44,307 shares during the last quarter. Cresset Asset Management LLC bought a new position in Hims & Hers Health during the first quarter valued at about $291,000. Northern Trust Corp increased its holdings in Hims & Hers Health by 19.5% during the first quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock worth $71,969,000 after buying an additional 397,310 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in Hims & Hers Health in the first quarter worth about $41,000. 63.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. Bank of America increased their target price on shares of Hims & Hers Health from $28.00 to $32.00 and gave the company an “underperform” rating in a research report on Tuesday, November 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday. UBS Group set a $32.00 price objective on Hims & Hers Health in a report on Tuesday, November 4th. Barclays started coverage on Hims & Hers Health in a research note on Monday, December 8th. They issued an “overweight” rating and a $48.00 target price on the stock. Finally, BTIG Research reiterated a “buy” rating and set a $85.00 price target on shares of Hims & Hers Health in a research note on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $45.50.

Insider Transactions at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 23,090 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $35.72, for a total value of $824,774.80. Following the completion of the transaction, the chief financial officer directly owned 94,333 shares in the company, valued at approximately $3,369,574.76. This trade represents a 19.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Patrick Harrison Carroll sold 10,021 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $367,870.91. Following the transaction, the insider directly owned 169,940 shares of the company’s stock, valued at approximately $6,238,497.40. This represents a 5.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 230,835 shares of company stock valued at $11,113,714. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $34.79 on Wednesday. Hims & Hers Health, Inc. has a one year low of $23.97 and a one year high of $72.98. The business has a fifty day moving average price of $41.06 and a 200-day moving average price of $48.17. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. The firm has a market capitalization of $7.92 billion, a P/E ratio of 64.42, a PEG ratio of 6.93 and a beta of 2.41.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The company had revenue of $598.98 million for the quarter, compared to the consensus estimate of $578.99 million. During the same quarter in the previous year, the firm posted $0.32 earnings per share. The business’s revenue for the quarter was up 49.2% compared to the same quarter last year. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health announced that its Board of Directors has initiated a share buyback program on Monday, November 17th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the company to buy up to 3% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its stock is undervalued.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.